GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02650206

CompletedPhase 1

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Effect of Liraglutide on Macrophage Polarization in Human Adipose Tissue and Peripheral Blood

Lead sponsor

Stanford University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI 25-42•HbA1c 6-7.9%

Primary endpoint

•Macrophage polarization

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02650206

Org study ID31063

Timeline

Milestones

Study first posted2016-01-08estimated

Primary completion2019-09-27actual

Study completion2019-09-27actual

Last update posted2020-06-09actual

Study start2015-01actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age40 Years

Maximum age69 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•BMI between 25 and 42 kg/m2

•Diet-controlled diabetics, or diabetics on Metformin that have permission from Primacy Care Physician to wash-out of the drug for 6 weeks prior to the study and for the duration of the study

•HbA1C between 6.0 - 7.9 (those on Metformin must have a HbA1c level below 7.5 prior to wash-out period)

•Fasting Blood Glucose < 150 mg/dl

•Women must be post-menopausal or surgically sterile within age range

•Subjects must live in vicinity of Stanford University

Exclusion criteria

•Prior Bariatric surgery

•Personal or family history of medullary thyroid cancer

•MEN2 Syndrome

•Thyroid Nodules (not evaluated by PCP)

•Pancreatitis (acute or chronic)

•Gallstones

•Fasting plasma triglycerides > 400 mg/dl

•Cardiovascular disease

•Major organ disease

•Unstable hypertension (BP >160/100 mm Hg)

•Heavy alcohol use

•Self-reported weight change of >2kg over past 6 weeks

•Medication known to affect blood glucose, insulin sensitivity, or inflammation

•NSAIDs (must cease use 4 weeks prior to study enrollment)

•Previous use of liraglutide, Januvia, Byetta, or Lira.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Other (unclassified)

Cardiometabolic biomarkers

2 endpoints

Secondary/protocol endpoint/low confidence

Inflammation, localized: Pro- and anti-inflammatory cytokines will be measured (IL6, IL-8, TNF-α, MCP-1, cell surface markers, and adiponectin) by rtPCR in adipose tissue and blood macrophages

Time frame:30 months

Adiponectin, change

change from baseline, improvement

componentshs-CRP, change, Adiponectin, change

Secondary/protocol endpoint

Inflammation, systemic: Plasma pro/anti-inflammatory cytokines: IL-6, hsCRP, cell surface markers, and adiponectin will be measured in plasma.

Time frame:30 months

descriptive, improvement

Other (unclassified)

2 endpoints

Primary/protocol endpoint/low confidence

Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry).

Time frame:30 months

descriptive

Secondary/protocol endpoint/low confidence

Macrophage polarization: M1 to M2 ratio in adipose tissue and peripheral blood according to cell surface markers (measured by flow cytometry)

Time frame:30 months

ratio, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.